South Korean biotechnology giant invests $280 million in Montgomery County site, preserving more than 500 jobs.
Annapolis, MD (JK) – South Korea’s largest biotechnology company, Samsung Biologics, is bringing its first United States manufacturing facility to Rockville, Maryland, marking a major international investment in the state’s life sciences sector. The announcement comes after Governor Moore and Maryland Commerce Secretary Harry Coker met with Samsung Biologics executives earlier this year during an international trade and investment mission to Japan and South Korea.
The company has acquired GSK’s Rockville manufacturing campus for $280 million and plans to expand drug substance production while upgrading technology to meet growing demand for biologic medicines. The facility will support both clinical and commercial manufacturing and is expected to play a key role in Samsung Biologics’ long-term U.S. growth strategy.
As part of the acquisition, Samsung Biologics will retain more than 500 existing employees at the Rockville site and create additional jobs, along with new opportunities for local suppliers. State and local leaders say the move strengthens Maryland’s position as one of the nation’s leading life sciences hubs, supported by a highly skilled workforce, research institutions, and federal agencies.
The announcement also builds on a wave of recent international investments across Maryland. These include a $2 billion AstraZeneca expansion in Frederick County and Gaithersburg, and additional job growth tied to corporate expansions in Washington County.
By Jimmy Key